专家视角:带状疱疹后神经痛的治疗与预防新思路

2013-09-17 宫晓倩 新华网健康频道

2013年9月11日,中国医科大学航空总医院多学科疼痛医学中心主任安建雄做客新华网,与网友交流带状疱疹后神经痛的治疗与预防。 安建雄指出带状疱疹俗称"缠腰龙"或"蛇盘疮",是由于体内病毒长期存在、不断繁殖,不断地破坏身体的神经引起的,常见于胸腰部,也可发生在头面部、脖子、四肢和会阴部。带状疱疹主要通过提高自身的免疫力进行预防,比如避免感冒、注意营养的平衡。增强自己的体质,病毒才不会繁殖。

2013年9月11日,中国医科大学航空总医院多学科疼痛医学中心主任安建雄做客新华网,与网友交流带状疱疹后神经痛的治疗与预防。

安建雄指出带状疱疹俗称"缠腰龙"或"蛇盘疮",是由于体内病毒长期存在、不断繁殖,不断地破坏身体的神经引起的,常见于胸腰部,也可发生在头面部、脖子、四肢和会阴部。带状疱疹主要通过提高自身的免疫力进行预防,比如避免感冒、注意营养的平衡。增强自己的体质,病毒才不会繁殖。日常饮食上要注意营养平衡,要多吃新鲜的蔬菜瓜果。

带状疱疹后神经痛是世界上最难治疗的痛症之一,有"不死的癌症"的恶名。安建雄指出带状疱疹后神经痛是带状疱疹痊愈以后仍然留有的疼痛,像火烧、针刺、刀割、砂纸打、稻草扎一样的神经病理疼痛。这种疼痛会长期存在,病人会非常痛苦。安建雄说60岁以上的带状疱疹患者慢性化或者形成疱疹后神经痛的概率非常高,而且随年龄增高发病率也增,80岁以上老人疱疹后神经痛发病率可高达75%以上。疼痛迁延不愈,有的长达数十年。

当问及带状疱疹后神经痛的治疗方法时,安建雄说经过长期研究,他带领的研究团队近两年改变了以往的治疗方针,采用新的思路,取得了突破性进展。一方面全面提高患者的抵抗力,用医用三氧等激活和提高病人免疫力,包括增加体内细胞因子和干扰素,这种方法即使不能完全杀死病毒,也可以抑制它的繁殖。另一方面采用微创介入疗法, 针对受损皮肤,神经根和神经节等病变部位进行阻滞和营养修复相配合的治疗方针,这种方法治疗周期一般为六到八周。



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2019273, encodeId=062f20192e320, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Wed Mar 19 03:17:00 CST 2014, time=2014-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691645, encodeId=3df4169164587, content=<a href='/topic/show?id=fa8148552d5' target=_blank style='color:#2F92EE;'>#带状疱疹后神经痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48552, encryptionId=fa8148552d5, topicName=带状疱疹后神经痛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=213529278967, createdName=jeanqiuqiu, createdTime=Wed Aug 13 00:17:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540799, encodeId=032e1540e99f4, content=<a href='/topic/show?id=ac8de440615' target=_blank style='color:#2F92EE;'>#神经痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74406, encryptionId=ac8de440615, topicName=神经痛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d8213287489, createdName=贵阳, createdTime=Thu Sep 19 05:17:00 CST 2013, time=2013-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580338, encodeId=68c21580338f4, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Thu Sep 19 05:17:00 CST 2013, time=2013-09-19, status=1, ipAttribution=)]
    2014-03-19 晓辰
  2. [GetPortalCommentsPageByObjectIdResponse(id=2019273, encodeId=062f20192e320, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Wed Mar 19 03:17:00 CST 2014, time=2014-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691645, encodeId=3df4169164587, content=<a href='/topic/show?id=fa8148552d5' target=_blank style='color:#2F92EE;'>#带状疱疹后神经痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48552, encryptionId=fa8148552d5, topicName=带状疱疹后神经痛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=213529278967, createdName=jeanqiuqiu, createdTime=Wed Aug 13 00:17:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540799, encodeId=032e1540e99f4, content=<a href='/topic/show?id=ac8de440615' target=_blank style='color:#2F92EE;'>#神经痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74406, encryptionId=ac8de440615, topicName=神经痛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d8213287489, createdName=贵阳, createdTime=Thu Sep 19 05:17:00 CST 2013, time=2013-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580338, encodeId=68c21580338f4, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Thu Sep 19 05:17:00 CST 2013, time=2013-09-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2019273, encodeId=062f20192e320, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Wed Mar 19 03:17:00 CST 2014, time=2014-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691645, encodeId=3df4169164587, content=<a href='/topic/show?id=fa8148552d5' target=_blank style='color:#2F92EE;'>#带状疱疹后神经痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48552, encryptionId=fa8148552d5, topicName=带状疱疹后神经痛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=213529278967, createdName=jeanqiuqiu, createdTime=Wed Aug 13 00:17:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540799, encodeId=032e1540e99f4, content=<a href='/topic/show?id=ac8de440615' target=_blank style='color:#2F92EE;'>#神经痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74406, encryptionId=ac8de440615, topicName=神经痛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d8213287489, createdName=贵阳, createdTime=Thu Sep 19 05:17:00 CST 2013, time=2013-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580338, encodeId=68c21580338f4, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Thu Sep 19 05:17:00 CST 2013, time=2013-09-19, status=1, ipAttribution=)]
    2013-09-19 贵阳
  4. [GetPortalCommentsPageByObjectIdResponse(id=2019273, encodeId=062f20192e320, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Wed Mar 19 03:17:00 CST 2014, time=2014-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691645, encodeId=3df4169164587, content=<a href='/topic/show?id=fa8148552d5' target=_blank style='color:#2F92EE;'>#带状疱疹后神经痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48552, encryptionId=fa8148552d5, topicName=带状疱疹后神经痛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=213529278967, createdName=jeanqiuqiu, createdTime=Wed Aug 13 00:17:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540799, encodeId=032e1540e99f4, content=<a href='/topic/show?id=ac8de440615' target=_blank style='color:#2F92EE;'>#神经痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74406, encryptionId=ac8de440615, topicName=神经痛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d8213287489, createdName=贵阳, createdTime=Thu Sep 19 05:17:00 CST 2013, time=2013-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580338, encodeId=68c21580338f4, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Thu Sep 19 05:17:00 CST 2013, time=2013-09-19, status=1, ipAttribution=)]

相关资讯

JAMA:抗肿瘤坏死因子治疗未升高带状疱疹风险

美国学者的一项研究表明,在类风湿性关节炎和其他炎性疾病患者中,抗肿瘤换死因子(TNF)新应用者未出现带状疱疹风险升高。论文发表于《美国医学会杂志》[JAMA2013, 309(9):887]。  此项研究在风湿性关节炎、炎性肠病以及银屑病、银屑病关节炎或强直性脊柱炎患者中确认了抗TNF新应用者。在各炎性疾病人群中对比抗TNF(33324例)和非生物性缓解病情抗风湿药(DMARD;25742例)新应

CMAJ:个体患带状疱疹并不会增加癌症风险

近日,刊登在国际杂志CMAJ (Canadian Medical Association Journal)上的一项研究表明,带状疱疹(Herpes zoster)并不会增加一般人群的癌症风险。 相比其它疾病来说,尽管带状疱疹是癌症病人常见的一种病症,那么是否带状疱疹的病人发生癌症的风险升高。尽管许多研究揭示了带状疱疹和癌症发生之间的关联,但是其具体联系,目前并不清楚。 一项对来自台湾35871

JID:既往带状疱疹史不影响疫苗的安全性

带状疱疹预防研究(SPS)是一项大型的随机双盲安慰剂对照的临床试验,涉及了38546名具有免疫力的、年龄大于60岁的成年人。研究发现,活性减毒带状疱疹疫苗(Oka/Merck VZV vaccine)能够减轻61%的带状疱疹相关的疼痛或不适,使带状疱疹后神经痛的发病率降低了67%,使带状疱疹的发病率降低了51%。因此,无论是否有过带状疱疹病史,CDCC和ACIP均推荐大于60岁的成年人接种带状疱疹

瑞金医院:免疫低下人群警惕带状疱疹

昼夜气温悄悄转凉,空气湿度开始降低,这正是疾病的高发时期,体质较差的人尤其要小心带状疱疹。带状疱疹是由水痘-带状疱疹病毒引起的一种以皮疹和较剧烈疼痛为特征的疾病。此病毒一般潜伏在脊髓后根神经元中,一旦机体抵抗力低下或劳累、感染、感冒发烧等,病毒可再次生长繁殖,并沿神经纤维移至皮肤,使受侵犯的神经和皮肤产生激烈的炎症。

FDA:美疾控中心更新水痘-带状疱疹病毒球蛋白的使用建议

美国疾病控制和预防中心(CDC)更新了使用水痘 - 带状疱疹病毒球蛋白(VariZIG)用于降低水痘 - 带状疱疹病毒(VZV)感染严重程度的的建议。 对于严重水痘高风险的人群,建议延长暴露后预防时间窗。作为研究新药,美国食品和药物管理局(FDA)最初批准VariZIG在4天之内使用,但根据7月19日发表在《Mortality and Morbidity Weekly Report》上的更新建议